Olema Pharmaceuticals, Inc.
OLMANasdaqCIK 1750284HealthcareFiscal year ends Dec 31
Reports and events: 106 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-1621:58 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000921895-26-002806 |
| 2026-10-1521:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-423002 |
| 2026-08-1311:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-347853 |
| 2026-08-1020:10 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-342383 |
| 2026-08-1020:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-342334 |
| 2026-06-2320:19 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-279483 |
| 2026-05-2611:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-237832 |
| 2026-05-2121:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-234848 |
| 2026-05-1211:10 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-218156 |
| 2026-05-1211:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-218142 |
| 2026-05-0121:27 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001193125-26-201751 |
| 2026-04-2920:36 ET | DEF 14A | Proxy statementPeriod 2026-04-29 | 0001193125-26-191956 |
| 2026-04-2920:34 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-191944 |
| 2026-03-1611:10 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-107169 |
| 2026-03-1611:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-107154 |
| 2026-01-3021:07 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-031792 |
| 2026-01-1221:44 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-010507 |
| 2025-11-1922:20 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-288343 |
| 2025-11-1821:23 ET | 8-K | 8.01 Other events | 0001193125-25-286206 |
| 2025-11-1012:10 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-273236 |
| 2025-11-1012:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-273228 |
| 2025-10-2021:13 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-243765 |
| 2025-09-0211:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001750284-25-000007 |
| 2025-08-1120:15 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-106565 |
| 2025-08-1120:08 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-106545 |
| 2025-06-1320:30 ET | 8-K | 5.07 Shareholder vote results | 0000950170-25-086256 |
| 2025-05-1323:29 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000935836-25-000324 |
| 2025-05-1320:15 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-070374 |
| 2025-05-1320:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-070291 |
| 2025-04-2820:30 ET | DEF 14A | Proxy statementPeriod 2025-04-28 | 0000950170-25-059348 |
| 2025-03-1820:15 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-041204 |
| 2025-03-1820:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-041186 |
| 2025-03-0512:15 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-033073 |
| 2025-01-1312:15 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-004563 |
| 2025-01-1021:01 ET | 8-K | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-25-004427 |
| 2024-12-1012:15 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-134759 |
| 2024-12-0400:49 ET | SC 13D/A | Ownership report, active investor, amended | 0000921895-24-002885 |
| 2024-12-0212:15 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-131965 |
| 2024-11-1221:15 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-125427 |
| 2024-11-1221:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-125384 |
| 2024-09-2711:00 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-109753 |
| 2024-08-0620:15 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-091836 |
| 2024-08-0620:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-091799 |
| 2024-07-0220:30 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0000950170-24-080546 |
| 2024-06-1420:39 ET | 8-K | 5.07 Shareholder vote results | 0000950170-24-073749 |
| 2024-06-0622:49 ET | SC 13D/A | Ownership report, active investor, amended | 0000935836-24-000426 |
| 2024-05-1511:06 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-060031 |
| 2024-05-0820:15 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-055686 |
| 2024-05-0820:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-055630 |
| 2024-04-2621:07 ET | DEF 14A | Proxy statementPeriod 2023-12-31 | 0000950170-24-049287 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.